Please wait while the formulary information is being retrieved.
Drug overview for LINCOMYCIN HCL (lincomycin hcl):
Generic name: LINCOMYCIN HCL (LIN-koe-MYE-sin)
Drug class: Antibiotics with Anaerobic Coverage
Therapeutic class: Anti-Infective Agents
Lincomycin, a lincosamide antibiotic, is structurally related to clindamycin.
No enhanced Uses information available for this drug.
Generic name: LINCOMYCIN HCL (LIN-koe-MYE-sin)
Drug class: Antibiotics with Anaerobic Coverage
Therapeutic class: Anti-Infective Agents
Lincomycin, a lincosamide antibiotic, is structurally related to clindamycin.
No enhanced Uses information available for this drug.
DRUG IMAGES
LINCOMYCIN HCL 600 MG/2 ML VL
The following indications for LINCOMYCIN HCL (lincomycin hcl) have been approved by the FDA:
Indications:
Pneumococcal infection
Staphylococcus infections
Streptococcal infection
Professional Synonyms:
Diplococcus pneumoniae infection
Fraenkel's Pneumococcus infection
Fraenkel-Weichselbaum Pneumococcus infection
Pneumococcus infection
Pneumonococcus infection
Staphylococcal infectious disease
Staphylococcus species infection
Staphylococcus spp. infection
Streptococcal infectious disease
Streptococcus pneumoniae infectious disease
Indications:
Pneumococcal infection
Staphylococcus infections
Streptococcal infection
Professional Synonyms:
Diplococcus pneumoniae infection
Fraenkel's Pneumococcus infection
Fraenkel-Weichselbaum Pneumococcus infection
Pneumococcus infection
Pneumonococcus infection
Staphylococcal infectious disease
Staphylococcus species infection
Staphylococcus spp. infection
Streptococcal infectious disease
Streptococcus pneumoniae infectious disease
The following dosing information is available for LINCOMYCIN HCL (lincomycin hcl):
Dosage of lincomycin hydrochloride is expressed in terms of lincomycin and depends on the severity of the infection.
The usual IM dosage of lincomycin for the treatment of serious staphylococcal or streptococcal infections in adults is 600 mg once every 24 hours. For the treatment of more severe infections, adults should receive 600 mg every 12 hours (or more frequently).
The usual IV dosage of lincomycin for the treatment of serious staphylococcal or streptococcal infections in adults is 600 mg to 1 g given every 8-12 hours. More severe infections may require increased dosage; in life-threatening infections, adults have received IV dosage as high as 8 g daily. The maximum recommended dosage for adults is 8 g daily.
For subconjunctival injection, a 75-mg dose of lincomycin results in ocular fluid concentrations that last 5 hours or longer and are sufficient for most susceptible bacteria.
The usual IM dosage of lincomycin for the treatment of serious staphylococcal or streptococcal infections in children older than 1 month of age is 10 mg/kg once every 24 hours. For more severe infections, children older than 1 month of age should receive 10 mg/kg every 12 hours (or more frequently).
The usual IV dosage of lincomycin for children older than 1 month of age is 10-20 mg/kg daily (depending on the severity of infection) administered in 2 or 3 equally divided doses.
The usual IM dosage of lincomycin for the treatment of serious staphylococcal or streptococcal infections in adults is 600 mg once every 24 hours. For the treatment of more severe infections, adults should receive 600 mg every 12 hours (or more frequently).
The usual IV dosage of lincomycin for the treatment of serious staphylococcal or streptococcal infections in adults is 600 mg to 1 g given every 8-12 hours. More severe infections may require increased dosage; in life-threatening infections, adults have received IV dosage as high as 8 g daily. The maximum recommended dosage for adults is 8 g daily.
For subconjunctival injection, a 75-mg dose of lincomycin results in ocular fluid concentrations that last 5 hours or longer and are sufficient for most susceptible bacteria.
The usual IM dosage of lincomycin for the treatment of serious staphylococcal or streptococcal infections in children older than 1 month of age is 10 mg/kg once every 24 hours. For more severe infections, children older than 1 month of age should receive 10 mg/kg every 12 hours (or more frequently).
The usual IV dosage of lincomycin for children older than 1 month of age is 10-20 mg/kg daily (depending on the severity of infection) administered in 2 or 3 equally divided doses.
Lincomycin hydrochloride is administered by IM injection or slow IV infusion. The drug should not be given by rapid IV injection. Lincomycin hydrochloride has been administered by subconjunctival injection. Although lincomycin has been administered orally, an oral preparation is not commercially available in the US.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for LINCOMYCIN HCL (lincomycin hcl):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Live Typhoid Vaccine/Antimicrobials SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1) CLINICAL EFFECTS: Vaccination may be ineffective. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3) DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3) |
VIVOTIF |
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Sodium Iodide I 131/Myelosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Sodium iodide I 131 can cause depression of the hematopoetic system. Myelosuppressives and immunomodulators also suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of sodium iodide I 131 with agents that cause bone marrow depression, including myelosuppressives or immunomodulators, may result in an enhanced risk of hematologic disorders, including anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia. Bone marrow depression may increase the risk of serious infections and bleeding.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of sodium iodide I 131 states that concurrent use with bone marrow depressants may enhance the depression of the hematopoetic system caused by large doses of sodium iodide I 131.(1) Sodium iodide I 131 causes a dose-dependent bone marrow suppression, including neutropenia or thrombocytopenia, in the 3 to 5 weeks following administration. Patients may be at increased risk of infections or bleeding during this time. Monitor complete blood counts within one month of therapy. If results indicate leukopenia or thrombocytopenia, dosimetry should be used to determine a safe sodium iodide I 131 activity.(1) DISCUSSION: Hematologic disorders including death have been reported with sodium iodide I 131. The most common hematologic disorders reported include anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia.(1) |
HICON, SODIUM IODIDE I-131 |
| Fecal Microbiota Spores/Antibiotics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1) CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1) DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores. |
VOWST |
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Neuromuscular Blocking Agents/Lincosamides SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Lincosamides appear to augment the neuromuscular blocking effects of nondepolarizing muscle relaxants. CLINICAL EFFECTS: The effects of nondepolarizing neuromuscular relaxants may be prolonged leading to profound sedation, respiratory depression, coma, and/or death. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Monitor respiratory function of the patient and provide the necessary support. In patients who have received nondepolarizing muscle relaxants, avoid use of lincosamides in the recovery room. If concurrent use is necessary, monitor patients for unusual dizziness or lightheadedness, extreme sleepiness, slowed or difficult breathing, or unresponsiveness. DISCUSSION: Lincomycin has been reported to augment the neuromuscular blocking effect of pancuronium in seven anesthetized patients. The effect was readily antagonized by neostigmine administration. In a case report, clindamycin produced prolonged neuromuscular blockade in a patient who had received pancuronium. Neostigmine was ineffective in antagonizing the blockade. |
ANECTINE, ATRACURIUM BESYLATE, BOTOX, BOTOX COSMETIC, CISATRACURIUM BESYLATE, DAXXIFY, DYSPORT, JEUVEAU, MYOBLOC, NIMBEX, QUELICIN, ROCURONIUM BROMIDE, SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE-NACL, VECURONIUM BROMIDE, VECURONIUM BROMIDE-WATER, XEOMIN |
The following contraindication information is available for LINCOMYCIN HCL (lincomycin hcl):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 4 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Clostridioides difficile infection |
| Myasthenia gravis |
| Severe hepatic disease |
There are 2 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Colitis |
| Kidney disease with likely reduction in glomerular filtration rate (GFr) |
The following adverse reaction information is available for LINCOMYCIN HCL (lincomycin hcl):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 22 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Clostridioides difficile infection |
Allergic dermatitis Azotemia Idiopathic thrombocytopenic purpura Neutropenic disorder Oliguria Proteinuria Pruritus of skin Skin rash Urticaria |
| Rare/Very Rare |
|---|
|
Acute generalized exanthematous pustulosis Angioedema Aplastic anemia Bullous dermatitis Cardiac arrest Erythema multiforme Exfoliative dermatitis Leukopenia Pancytopenia Serum sickness Stevens-johnson syndrome Toxic epidermal necrolysis |
There are 18 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Diarrhea Nausea Vomiting |
Hypotension Vaginitis |
| Rare/Very Rare |
|---|
|
Abnormal hepatic function tests Anaphylaxis Dizziness Drowsy Glossitis Headache disorder Injection site pain Injection site sequelae Kidney disease with reduction in glomerular filtration rate (GFr) Stomatitis Thrombophlebitis Tinnitus Vertigo |
The following precautions are available for LINCOMYCIN HCL (lincomycin hcl):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Animal reproduction studies have not been performed with lincomycin to evaluate the teratogenic potential of the drug, and there are no adequate and well-controlled studies using the drug in pregnant women. Lincomycin should be used during pregnancy only when clearly needed. Reproduction studies in rats using oral lincomycin dosages up to 1000 mg/kg (1.2 times the maximum daily human dosage based on mg/m2) have not revealed adverse effects on survival of offspring from birth to weaning.
Lincomycin hydrochloride injection contains benzyl alcohol as a preservative; benzyl alcohol can cross the placenta. (See Cautions: Pediatric Precautions.)
Lincomycin hydrochloride injection contains benzyl alcohol as a preservative; benzyl alcohol can cross the placenta. (See Cautions: Pediatric Precautions.)
Lincomycin is distributed into milk. Because of the potential for serious adverse reactions from lincomycin in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for LINCOMYCIN HCL (lincomycin hcl):
WARNING: This medication may rarely cause a severe intestinal condition due to a bacteria called C. difficile. This condition may occur during treatment or weeks to months after treatment has stopped.
Tell your doctor right away if you develop: diarrhea that doesn't stop, abdominal or stomach pain/cramping, blood/mucus in your stool. If you have these symptoms, do not use anti-diarrhea or opioid products because they may make symptoms worse.
WARNING: This medication may rarely cause a severe intestinal condition due to a bacteria called C. difficile. This condition may occur during treatment or weeks to months after treatment has stopped.
Tell your doctor right away if you develop: diarrhea that doesn't stop, abdominal or stomach pain/cramping, blood/mucus in your stool. If you have these symptoms, do not use anti-diarrhea or opioid products because they may make symptoms worse.
The following icd codes are available for LINCOMYCIN HCL (lincomycin hcl)'s list of indications:
| Pneumococcal infection | |
| A40.3 | Sepsis due to streptococcus pneumoniae |
| B95.3 | Streptococcus pneumoniae as the cause of diseases classified elsewhere |
| G00.1 | Pneumococcal meningitis |
| J13 | Pneumonia due to streptococcus pneumoniae |
| M00.1 | Pneumococcal arthritis and polyarthritis |
| M00.10 | Pneumococcal arthritis, unspecified joint |
| M00.11 | Pneumococcal arthritis, shoulder |
| M00.111 | Pneumococcal arthritis, right shoulder |
| M00.112 | Pneumococcal arthritis, left shoulder |
| M00.119 | Pneumococcal arthritis, unspecified shoulder |
| M00.12 | Pneumococcal arthritis, elbow |
| M00.121 | Pneumococcal arthritis, right elbow |
| M00.122 | Pneumococcal arthritis, left elbow |
| M00.129 | Pneumococcal arthritis, unspecified elbow |
| M00.13 | Pneumococcal arthritis, wrist |
| M00.131 | Pneumococcal arthritis, right wrist |
| M00.132 | Pneumococcal arthritis, left wrist |
| M00.139 | Pneumococcal arthritis, unspecified wrist |
| M00.14 | Pneumococcal arthritis, hand |
| M00.141 | Pneumococcal arthritis, right hand |
| M00.142 | Pneumococcal arthritis, left hand |
| M00.149 | Pneumococcal arthritis, unspecified hand |
| M00.15 | Pneumococcal arthritis, hip |
| M00.151 | Pneumococcal arthritis, right hip |
| M00.152 | Pneumococcal arthritis, left hip |
| M00.159 | Pneumococcal arthritis, unspecified hip |
| M00.16 | Pneumococcal arthritis, knee |
| M00.161 | Pneumococcal arthritis, right knee |
| M00.162 | Pneumococcal arthritis, left knee |
| M00.169 | Pneumococcal arthritis, unspecified knee |
| M00.17 | Pneumococcal arthritis, ankle and foot |
| M00.171 | Pneumococcal arthritis, right ankle and foot |
| M00.172 | Pneumococcal arthritis, left ankle and foot |
| M00.179 | Pneumococcal arthritis, unspecified ankle and foot |
| M00.18 | Pneumococcal arthritis, vertebrae |
| M00.19 | Pneumococcal polyarthritis |
| Staphylococcus infections | |
| A41.0 | Sepsis due to staphylococcus aureus |
| A41.01 | Sepsis due to methicillin susceptible staphylococcus aureus |
| A41.02 | Sepsis due to methicillin resistant staphylococcus aureus |
| A41.1 | Sepsis due to other specified staphylococcus |
| A41.2 | Sepsis due to unspecified staphylococcus |
| A49.0 | Staphylococcal infection, unspecified site |
| A49.01 | Methicillin susceptible staphylococcus aureus infection, unspecified site |
| A49.02 | Methicillin resistant staphylococcus aureus infection, unspecified site |
| B95.6 | Staphylococcus aureus as the cause of diseases classified elsewhere |
| B95.61 | Methicillin susceptible staphylococcus aureus infection as the cause of diseases classified elsewhere |
| B95.62 | Methicillin resistant staphylococcus aureus infection as the cause of diseases classified elsewhere |
| B95.7 | Other staphylococcus as the cause of diseases classified elsewhere |
| B95.8 | Unspecified staphylococcus as the cause of diseases classified elsewhere |
| G00.3 | Staphylococcal meningitis |
| J15.2 | Pneumonia due to staphylococcus |
| J15.20 | Pneumonia due to staphylococcus, unspecified |
| J15.21 | Pneumonia due to staphylococcus aureus |
| J15.211 | Pneumonia due to methicillin susceptible staphylococcus aureus |
| J15.212 | Pneumonia due to methicillin resistant staphylococcus aureus |
| J15.29 | Pneumonia due to other staphylococcus |
| L00 | Staphylococcal scalded skin syndrome |
| M00.0 | Staphylococcal arthritis and polyarthritis |
| M00.00 | Staphylococcal arthritis, unspecified joint |
| M00.01 | Staphylococcal arthritis, shoulder |
| M00.011 | Staphylococcal arthritis, right shoulder |
| M00.012 | Staphylococcal arthritis, left shoulder |
| M00.019 | Staphylococcal arthritis, unspecified shoulder |
| M00.02 | Staphylococcal arthritis, elbow |
| M00.021 | Staphylococcal arthritis, right elbow |
| M00.022 | Staphylococcal arthritis, left elbow |
| M00.029 | Staphylococcal arthritis, unspecified elbow |
| M00.03 | Staphylococcal arthritis, wrist |
| M00.031 | Staphylococcal arthritis, right wrist |
| M00.032 | Staphylococcal arthritis, left wrist |
| M00.039 | Staphylococcal arthritis, unspecified wrist |
| M00.04 | Staphylococcal arthritis, hand |
| M00.041 | Staphylococcal arthritis, right hand |
| M00.042 | Staphylococcal arthritis, left hand |
| M00.049 | Staphylococcal arthritis, unspecified hand |
| M00.05 | Staphylococcal arthritis, hip |
| M00.051 | Staphylococcal arthritis, right hip |
| M00.052 | Staphylococcal arthritis, left hip |
| M00.059 | Staphylococcal arthritis, unspecified hip |
| M00.06 | Staphylococcal arthritis, knee |
| M00.061 | Staphylococcal arthritis, right knee |
| M00.062 | Staphylococcal arthritis, left knee |
| M00.069 | Staphylococcal arthritis, unspecified knee |
| M00.07 | Staphylococcal arthritis, ankle and foot |
| M00.071 | Staphylococcal arthritis, right ankle and foot |
| M00.072 | Staphylococcal arthritis, left ankle and foot |
| M00.079 | Staphylococcal arthritis, unspecified ankle and foot |
| M00.08 | Staphylococcal arthritis, vertebrae |
| M00.09 | Staphylococcal polyarthritis |
| P23.2 | Congenital pneumonia due to staphylococcus |
| P36.2 | Sepsis of newborn due to staphylococcus aureus |
| P36.3 | Sepsis of newborn due to other and unspecified staphylococci |
| P36.30 | Sepsis of newborn due to unspecified staphylococci |
| P36.39 | Sepsis of newborn due to other staphylococci |
| Streptococcal infection | |
| A38 | Scarlet fever |
| A38.0 | Scarlet fever with otitis media |
| A38.1 | Scarlet fever with myocarditis |
| A38.8 | Scarlet fever with other complications |
| A38.9 | Scarlet fever, uncomplicated |
| A40 | Streptococcal sepsis |
| A40.0 | Sepsis due to streptococcus, group A |
| A40.1 | Sepsis due to streptococcus, group B |
| A40.3 | Sepsis due to streptococcus pneumoniae |
| A40.8 | Other streptococcal sepsis |
| A40.9 | Streptococcal sepsis, unspecified |
| A48.3 | Toxic shock syndrome |
| A49.1 | Streptococcal infection, unspecified site |
| B95.0 | Streptococcus, group a, as the cause of diseases classified elsewhere |
| B95.1 | Streptococcus, group b, as the cause of diseases classified elsewhere |
| B95.3 | Streptococcus pneumoniae as the cause of diseases classified elsewhere |
| B95.4 | Other streptococcus as the cause of diseases classified elsewhere |
| B95.5 | Unspecified streptococcus as the cause of diseases classified elsewhere |
| G00.1 | Pneumococcal meningitis |
| G00.2 | Streptococcal meningitis |
| J02.0 | Streptococcal pharyngitis |
| J03.0 | Streptococcal tonsillitis |
| J03.00 | Acute streptococcal tonsillitis, unspecified |
| J03.01 | Acute recurrent streptococcal tonsillitis |
| J13 | Pneumonia due to streptococcus pneumoniae |
| J15.3 | Pneumonia due to streptococcus, group B |
| J15.4 | Pneumonia due to other streptococci |
| J20.2 | Acute bronchitis due to streptococcus |
| M00.1 | Pneumococcal arthritis and polyarthritis |
| M00.10 | Pneumococcal arthritis, unspecified joint |
| M00.11 | Pneumococcal arthritis, shoulder |
| M00.111 | Pneumococcal arthritis, right shoulder |
| M00.112 | Pneumococcal arthritis, left shoulder |
| M00.119 | Pneumococcal arthritis, unspecified shoulder |
| M00.12 | Pneumococcal arthritis, elbow |
| M00.121 | Pneumococcal arthritis, right elbow |
| M00.122 | Pneumococcal arthritis, left elbow |
| M00.129 | Pneumococcal arthritis, unspecified elbow |
| M00.13 | Pneumococcal arthritis, wrist |
| M00.131 | Pneumococcal arthritis, right wrist |
| M00.132 | Pneumococcal arthritis, left wrist |
| M00.139 | Pneumococcal arthritis, unspecified wrist |
| M00.14 | Pneumococcal arthritis, hand |
| M00.141 | Pneumococcal arthritis, right hand |
| M00.142 | Pneumococcal arthritis, left hand |
| M00.149 | Pneumococcal arthritis, unspecified hand |
| M00.15 | Pneumococcal arthritis, hip |
| M00.151 | Pneumococcal arthritis, right hip |
| M00.152 | Pneumococcal arthritis, left hip |
| M00.159 | Pneumococcal arthritis, unspecified hip |
| M00.16 | Pneumococcal arthritis, knee |
| M00.161 | Pneumococcal arthritis, right knee |
| M00.162 | Pneumococcal arthritis, left knee |
| M00.169 | Pneumococcal arthritis, unspecified knee |
| M00.17 | Pneumococcal arthritis, ankle and foot |
| M00.171 | Pneumococcal arthritis, right ankle and foot |
| M00.172 | Pneumococcal arthritis, left ankle and foot |
| M00.179 | Pneumococcal arthritis, unspecified ankle and foot |
| M00.18 | Pneumococcal arthritis, vertebrae |
| M00.19 | Pneumococcal polyarthritis |
| M00.2 | Other streptococcal arthritis and polyarthritis |
| M00.20 | Other streptococcal arthritis, unspecified joint |
| M00.21 | Other streptococcal arthritis, shoulder |
| M00.211 | Other streptococcal arthritis, right shoulder |
| M00.212 | Other streptococcal arthritis, left shoulder |
| M00.219 | Other streptococcal arthritis, unspecified shoulder |
| M00.22 | Other streptococcal arthritis, elbow |
| M00.221 | Other streptococcal arthritis, right elbow |
| M00.222 | Other streptococcal arthritis, left elbow |
| M00.229 | Other streptococcal arthritis, unspecified elbow |
| M00.23 | Other streptococcal arthritis, wrist |
| M00.231 | Other streptococcal arthritis, right wrist |
| M00.232 | Other streptococcal arthritis, left wrist |
| M00.239 | Other streptococcal arthritis, unspecified wrist |
| M00.24 | Other streptococcal arthritis, hand |
| M00.241 | Other streptococcal arthritis, right hand |
| M00.242 | Other streptococcal arthritis, left hand |
| M00.249 | Other streptococcal arthritis, unspecified hand |
| M00.25 | Other streptococcal arthritis, hip |
| M00.251 | Other streptococcal arthritis, right hip |
| M00.252 | Other streptococcal arthritis, left hip |
| M00.259 | Other streptococcal arthritis, unspecified hip |
| M00.26 | Other streptococcal arthritis, knee |
| M00.261 | Other streptococcal arthritis, right knee |
| M00.262 | Other streptococcal arthritis, left knee |
| M00.269 | Other streptococcal arthritis, unspecified knee |
| M00.27 | Other streptococcal arthritis, ankle and foot |
| M00.271 | Other streptococcal arthritis, right ankle and foot |
| M00.272 | Other streptococcal arthritis, left ankle and foot |
| M00.279 | Other streptococcal arthritis, unspecified ankle and foot |
| M00.28 | Other streptococcal arthritis, vertebrae |
| M00.29 | Other streptococcal polyarthritis |
| P23.3 | Congenital pneumonia due to streptococcus, group B |
| P36.0 | Sepsis of newborn due to streptococcus, group B |
| P36.1 | Sepsis of newborn due to other and unspecified streptococci |
| P36.10 | Sepsis of newborn due to unspecified streptococci |
| P36.19 | Sepsis of newborn due to other streptococci |
Formulary Reference Tool